Compare Equitable Holdings Inc. Common Stock (EQH) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equitable Holdings Inc. Common Stock vs Sanofi SA — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.49B), while Sanofi SA trades at $39.99 (market cap $94.58B). The key difference: Sanofi SA is far larger — about 6.5× Equitable Holdings Inc. Common Stock's market cap, and Sanofi SA pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and Sanofi SA for 94 Days on average.
| EQH | SNY | |
|---|---|---|
Market Cap | $14.49B | $94.58B |
Volume | 2,405,401 | 3,988,460 |
Sector | Financials | Health |
52-Week High | $54.50 | $52.34 |
52-Week Low | $35.34 | $39.12 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $5.54B | $113.80B |
Dividend Yield | 2.15% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
SNY trades at $39.77, up 0.08% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and announced a significant expansion of its immunology alliance with Regeneron, valued up to $8 billion. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%.
The outlook is mixed; recent collaborations and earnings beats provide growth catalysts, but a projected decline in 2026 net income to $4.0 billion and bearish technical indicators suggest near-term headwinds. Risks include execution of new partnerships and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
